Psychopharmakotherapie einer ambulanten und stationären Inanspruchnahmepopulation adoleszenter Patienten mit Borderline-Persönlichkeitsstörung
Abstract
Fragestellung: Ein Großteil erwachsener Patienten mit Borderline-Persönlichkeitsstörung (BPS) wird mit Psychopharmaka behandelt. Über die Psychopharmakotherapie bei Adoleszenten mit BPS liegen bisher keine Daten vor. Ziel dieser Studie ist die Untersuchung der Häufigkeit des Störungsbildes und des Verschreibungsverhaltens bei adoleszenten ambulanten und stationären Patienten mit BPS. Methoden: 58 adoleszente Patienten mit BPS (16.7 ± 2.5 Jahre) einer Inanspruchnahmepopulation während eines 7-jährigen Beobachtungszeitraums wurden retrospektiv hinsichtlich der Medikation und verschiedener Risikovariablen in der Erstbehandlungsepisode untersucht. Ergebnisse: 37 Patienten wurden stationär und 21 ambulant behandelt, entsprechend einer Prävalenz von 2.1 %, bezogen auf die Inanspruchnahmepopulation. Stationäre Patienten waren insgesamt stärker durch Risikofaktoren belastet (ca. 68 % mit komorbiden Störungen, ca. 49 % mit selbstverletzendem Verhalten, signifikant (p < .001) mehr Suizidversuche in der Vorgeschichte) und wurden häufiger (p < .001) psychopharmakologisch behandelt. Am häufigsten wurden Antidepressiva verschrieben (SSRI und NaSSA), gefolgt von Neuroleptika. Über die Hälfte der medizierten Patienten erhielten mehrere Medikamente gleichzeitig. Schlussfolgerungen: Psychopharmakotherapie bei BPS hat inzwischen einen hohen Stellenwert, ist in erster Linie symptomorientiert und komorbide Störungen sollten gleichermaßen miteinbezogen werden. Auch für Adoleszente gewinnt die Medikation bei BPS an Bedeutung. Stationär behandelte Patienten sind durch psychiatrische Risikofaktoren stärker belastet und werden häufiger mediziert.
Objective: The majority of adult patients with borderline personality disorder (BPD) are treated with psychotropic drugs. However, there are no data on psychotropic therapy in adolescents. This study examines the prevalence of BPD in an adolescent population undergoing either inpatient or outpatient psychiatric treatment and assesses psychotropic prescription patterns in adolescent in- and outpatients with BPD. Methods: Out of a population of adolescents undergoing psychiatric treatment over a seven-year observation period, 58 adolescent patients with BPD (16.7 ± 2.5 years) were investigated retrospectively with regard to their first episode of treatment, type of medication, and different risk variables. Results: Out of the investigated population, 37 inpatients and 21 outpatients received treatment. Inpatients were shown to have higher rates of risk variables (approx. 68% with co-morbid disorders and approx. 49% with self-harmful behaviour, significantly (p < .001) more attempted suicides in their patient history) and higher rates of psychotropic treatment (p < .001). Antidepressants (SSRI and NaSSA) were most commonly prescribed, followed by neuroleptics. More than 50% of the medicated patients were treated with multiple psychotropic drugs administered simultaneously. Conclusions: Pharmacotherapy in BPD has a high and increasing therapeutic value, with the prescription of psychotropic drugs being primarily symptom-orientated. Pharmacotherapy of co-morbid disorders should be accorded equal treatment priority. In line with this, psychotropic treatment of BPD in adolescents is increasingly important. Inpatient adolescents are more burdened in terms of psychiatric risk variables, and also receive medication more often.
Literatur
1985). Borderline: An adjective in search of a noun. Journal of Clinical Psychiatry, 46, 41–48.
(2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
(2001). Practice guidelines for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158, 1–52.
(2005). Psychopharmakotherapie und andere somatische Behandlungen. In , Leitlinien zur Behandlung der Borderline Persönlichkeitsstörung. (1. Auflage, S. 46–58 & 103–119). Bern: Huber.
(2002). Diagnostic efficiency of borderline personality disorder criteria in hospitalized adolescents: Comparison with hospitalized adults. American Journal of Psychiatry, 159, 2042–2047.
(2006). Combined treatment of major depression in patients with borderline personality disorder: A comparison with pharmacotherapy. Canadian Journal of Psychiatry, 51, 453–460.
(2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104–109.
(2002). Pharmakotherapie. In , Borderline-Störung, Fortschritte der Psychotherapie, Band 14 (1. Aufl., S. 121–122). Göttingen: Hogrefe-Verlag.
(2000). Persönlichkeitsstörungen im Jugendalter. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 28, 5–15.
(2006). Prevalence and correlates of personality disorder in Great Britain. British Journal of Psychiatry, 188, 423–431.
(1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479–486.
(2006). Dialektisch-Behaviorale Therapie für Adoleszente (DBT-A) – eine Pilotstudie zur Therapie von Suizidalität, Parasuizidalität und selbstverletzenden Verhaltensweisen bei Patientinnen mit Symptomen einer Borderlinestörung. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 34, 15–27.
(2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442–446.
(2008). Antidepressants use in pediatric populations. Expert Opinion on Drug Safety, 7, 223–225.
(2005). Pharmakotherapie. In , Borderline. Diagnostik, Therapie, Forschung (1. Aufl., S. 153–182). Bern: Huber.
(2006). Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. American Journal of Psychiatry, 163, 1173–1178.
(2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332–339.
(2005). Pharmacotherapy of personality disorders in german speaking countries: State and changes in the last decade. Pharmacopsychiatry, 38, 201–205.
(2007). World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for biological treatment of personality disorders. The World Journal of Biological Psychiatry, 8, 212–244.
(2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality. Journal of Clinical Psychiatry, 62, 199–203.
(2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621–624.
(2006). Suizidalität bei depressiven Kindern und Jugendlichen unter Behandlung mit selektiven Serotoninwiederaufnahmehemmern. Der Nervenarzt, 77, 1332–1337.
(2001). Spezifische Persönlichkeits- und Verhaltensstörungen. In , Multiaxiales Klassifikationsschema für psychische Störungen des Kindes- und Jugendalters (4. Aufl., S. 248–254). Bern: Huber.
(1995). International Psychopharmacology Algorithm Project report. Psychopharmacology Bulletin, 31, 457–507.
(2007). Medikamentöse Therapie der Depression bei Kindern und Jugendlichen. Praxis der Kinderpsychologie und Kinderpsychiatrie, 56, 224–233.
(2006). Persönlichkeitsmerkmale im Kindes- und Jugendalter: Konzepte, methodische Ansätze und empirische Ergebnisse. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 34, 87–100.
(2004). Borderline personality disorder. Lancet, 364, 453–461.
(2006). Topiramate treatment for women with borderline personality disorder. Journal of Clinical Psychopharmacology, 26, 61–66.
(1992). Prevalences of personality disorders (DSM-III-R) in the community. Journal of Personality Disorders, 6, 187–196.
(1986). The Chestnut Lodge follow-up study; 3: Long-term outcome of borderline personalities. Archives of General Psychiatry, 43, 20–30.
(2007). Behandlung der Borderline-Persönlichkeitsstörung mit atypischen Antipsychotika. Der Nervenarzt, 78, 1003–1013.
(2005). Depression in children and young people identification and management in primary, community and secondary care. National Clinical Practice Guideline Number 28, developed by National Collaborating Centre for Mental Health commissioned by the National Institute for Clinical Excellence published by The British Psychological Society & The Royal College of Psychiatrists.
(2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double blind, placebo-controlled trial. American Journal of Psychiatry, 163, 833–838.
(2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry, 57, 495–499.
(2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515–1519.
(2006). Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 21, 345–353.
(2005a). Recent advances in the treatment of borderline personality disorder. Canadian Journal of Psychiatry, 50, 435–441.
(2005b). Outcome and epidemiological research on personality disorders: Implications for classification. Journal of Personality Disorders, 19, 557–562.
(2008). Attention deficit/hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. British Journal of Psychiatry, 192, 118–123.
(2004). Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry, 65, 1414–1419.
(2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196–199.
(1983). The validity of DSM-III borderline personality disorder. Archives of General Psychiatry, 40, 23–30.
(2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive development disorders. Journal of Child and Adolescent Psychopharmacology, 11, 267–277.
(2006). Pharmakologische und psychotherapeutische Behandlung der Borderline-Störung. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54, 185–197.
(2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048–2054.
(2008). Diagnostik von Persönlichkeitsstörungen im Jugendalter nach SKID-II. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 36, 117–125.
(1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23–29.
(2001). Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung. Fortschritte der Neurologie- Psychiatrie, 69, 310–321.
(2008). Konzeptuelle Fragen und Behandlungsansätze bei Persönlichkeitsstörungen im Jugendalter. Praxis der Kinderpsychologie und Kinderpsychiatrie, 57, 625–640.
(2006). Comparison of symptoms and treatments of adults and adolescents with borderline personality disorder. International Journal of Adolescent Medicine and Health, 18, 215–220.
(1997). Borderline disorder in Turkey: A 2- to 4-year follow-up. Social Psychiatry and Psychiatric Epidemiology, 32, 109–112.
(2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379–385.
(2005). Double-blind, placebo-controlled study of dialectical behaviour therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221–1224.
(2000). Psychopharmacological treatment of borderline personality disorder. The Psychiatric Clinics of North America, 23, 169–192.
(2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression treatment for adolescents with depression study (TADS) randomized controlled trial. Journal of the American Medical Association (JAMA), 292, 807–820.
(2005). The treatment for adolescents with depression study (TADS): Demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 28–40.
(2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19, 287–291.
(2008). Efficacy of antidepressants in juvenile depression: Meta-analysis. The British Journal of Psychiatry, 193, 10–17.
(2003). Persönlichkeitsstörungen. In , Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (2. Auflage, S. 141–152). Köln: Deutscher Ärzte-Verlag.
(2007). Persönlichkeitsstörungen. In , Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (3. Auflage; S. 141–152). Köln: Deutscher Ärzte-Verlag.
(2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849–854.
(2003). Omega-3-fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167–169.
(2004). Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. American Journal of Psychiatry, 161, 2108–2114.
(2004). Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for six years. Journal of Clinical Psychiatry, 65, 28–36.
(2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903–907.
(